Clinical Trials in Houston

Showing 5301-5320 of 13,620 trials

A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

NCT02829723

The purpose of this first-in-human (FIH) study of BLZ945 given as a single agent or in combination with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLZ945, administered orally, as a single agent or in combination with PDR001, administered intravenously (i.v.) in adult patients with advanced solid tumors.

Advanced Solid Tumors

Novartis Pharmaceuticals192 participantsStarted Oct 2016

Boston, Massachusetts, United States • Nashville, Tennessee, United States • Houston, Texas, United States +11 more locations

TERMINATEDPhase 3< 1 mile

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

NCT03443973

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will be performed at the end of the double blind period at week 116. Participants will then be offered to enter into an open-label extension (OLE). Participants not willing to go to the OLE will participate in a long term follow-up period for up to 50 weeks after the last gantenerumab dose.

Alzheimer Disease

Hoffmann-La Roche975 participantsStarted Aug 2018

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Sun City, Arizona, United States +152 more locations

A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Find Trials by Condition in Houston

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

B0151005 Open-Label Extension Study

Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A

Pentoxifylline Therapy in Biliary Atresia

Congenital Heart Disease: Impact on Learning and Development in Down Syndrome (CHILD-DS)

A Study of PTC923 in Participants With Phenylketonuria

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung

A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)

Study of Probable Benefit of the Neuro-Spinal Scaffold™ in Subjects With Complete Thoracic AIS A Spinal Cord Injury as Compared to Standard of Care

Study Evaluating Betrixaban in Pediatric Participants

Prospective Clinicogenomic Program

A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT

The Effect of In-utero Exposure to Metformin in 5-11 Year Old Offspring of Mothers in the MiTy Trial

A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer